search returned 100 results for adalimumab, showing results 91 to 100
and had been stable on
adalimumab for ankylosing spondylitis. Despite documentation of prior use
https://rheumatology.org.au/LinkClick.aspx?fileticket=4hcCcsBBYJM%3d&portalid=2
Adalimumab
https://rheumatology.org.au/For-Patients/Adult-Medication-Information/A-B
Adalimumab now TGA listed for chronic non-infectious anterior uveitis in paediatric
patients 2 years of age..., or in whom conventional therapy is inappropriate.
o Paediatric Adalimumab enthesitis or spondylitis
https://rheumatology.org.au/LinkClick.aspx?fileticket=bE3QGoIHJSA%3d
anti-rheumatic
drugs include the following medicines: abatacept, adalimumab, anakinra, baricitinib... of age or more.
*TNFI’s include: adalimumab, certolizumab, etanercept, golimumab and
infliximab
https://rheumatology.org.au/LinkClick.aspx?fileticket=%2bZsa0YE2nrg%3d
Adalimumab now TGA listed for chronic non-infectious anterior uveitis in paediatric
patients 2 years of age..., or in whom conventional therapy is inappropriate.
o Paediatric Adalimumab enthesitis or spondylitis
https://rheumatology.org.au/LinkClick.aspx?fileticket=bE3QGoIHJSA%3d&portalid=2
meeting:
o adalimumab for vision threatening non-infectious uveitis
o anifrolumab for Systemic... contributed.
• WR also mentioned the ambitious submission of adalimumab for immune-mediated
https://rheumatology.org.au/LinkClick.aspx?fileticket=4J7nSL31Wnc%3d
recommendations meeting
o adalimumab for vision threatening non-infectious uveitis.
o anifrolumab...) and psoriatic arthritis (PsA).
• Ambitious submission of adalimumab for immune-mediated
https://rheumatology.org.au/LinkClick.aspx?fileticket=el6EIvOwZvg%3d
adalimumab, certolizumab, etanercept, golimumab and infliximab.
Household contacts of immunosuppressed... (adalimumab, certolizumab, etanercept,
golimumab and infliximab)
tsDMARDs targeted synthetic disease
https://rheumatology.org.au/LinkClick.aspx?fileticket=6ohMVnwv6eY%3d
meeting:
o adalimumab for vision threatening non-infectious uveitis
o anifrolumab for Systemic... contributed.
• WR also mentioned the ambitious submission of adalimumab for immune-mediated
https://rheumatology.org.au/LinkClick.aspx?fileticket=4J7nSL31Wnc%3d&portalid=2
recommendations meeting
o adalimumab for vision threatening non-infectious uveitis.
o anifrolumab...) and psoriatic arthritis (PsA).
• Ambitious submission of adalimumab for immune-mediated
https://rheumatology.org.au/LinkClick.aspx?fileticket=el6EIvOwZvg%3d&portalid=2